UK / Pharma Industry Warns of Declining Competitiveness
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Address: Unit 6 Regents Drive,
Low Prudhoe Industrial Estate, Northumberland.
NE42 6PX.,United Kingdom
Tel: +44 (0) 1661 833 693
Web: www.scmpharma.com
SCM Pharma is a UK-based contract development and manufacturing organisation (CDMO) that develops and delivers novel, difficult and dangerous drugs on behalf of its clients. The company works with clients progressing drugs through the pre-clinical formulation stage, clinical trials and others that require low volume commercial supply of niche licensed products.
Privately-owned, SCM Pharma’s corporate HQ and MHRA-licensed manufacturing facilities are located in North East England with recently acquired additional laboratory space within the University of Sunderland’s state-of-the-art £8.5m science complex. Its clients include top 10 big pharma, speciality pharmaceutical companies, small biotech firms, virtual companies, public sector bodies and academic institutions from across Europe and North America.
With specific expertise in custom formulation, complex cGMP sterile manufacturing and aseptic filling, the award-winning CDMO is able to handle 14C radiolabeled compounds and potent products including cytotoxics. Its specialist offerings include –
• Process development
• Formulation development
• Aseptic processing (using isolator technology)
• Non-aseptic processing followed by terminal sterilisation
• GMP filling of 14C radiolabeled compounds
• Fill/¬finish of highly potent products including cytotoxic and cytostatic formulations
• Drug/medical device fi¬lling and assembly
• In-house testing including sterility, endotoxin, microbiology and analytical chemistry
• ICH stability testing
• Clinical packaging and distribution
• QP release
SCM Pharma can fill liquids, gels and powders into a range of final dosage forms including ampoules, vials, cartridges, syringes, bottles.
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV),…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
National Health Service (NHS) England CEO Amanda Pritchard has raised concerns about the state of British healthcare in recent weeks and months, proclaiming that the NHS is in a worse…
With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from…
“Life sciences are at the heart of my vision to build a country fit for the future,” tweeted new UK Prime Minister Liz Truss last month. Now installed as leader…
US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion…
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
See our Cookie Privacy Policy Here